Karyopharm Therapeutics (NASDAQ:KPTI) had its target price boosted by equities research analysts at Wedbush from $18.99 to $26.00 in a research note issued on Tuesday, BenzingaRatingsTable reports. The brokerage presently has a “neutral” rating on the stock. Wedbush’s target price suggests a potential upside of 28.33% from the stock’s current price. Other equities research analysts […]
